CANCER OF THE BLADDER
Cancer of the urinary bladder is more common in people aged 50 to 70 years. It affects men more than women (3:1) and is more common in whites than in African Americans. Bladder cancer is the fourth leading cause of cancer in American men, accounting for more than 12,000 deaths in the U.S. annually (American Cancer Society, 2002). Bladder cancer has a high worldwide in-cidence (Amling, 2001). Bladder tumors account for nearly 1 in 25 cancers diagnosed in the United States. There are two forms of bladder cancer: superficial (which tends to recur) and invasive. About 80% to 90% of all bladder cancers are transitional cell (which means they arise from the transitional cells of the blad-der); the remaining types of tumors are squamous cell and ade-nocarcinoma. Research has demonstrated that many individuals with bladder cancer for which a total cystectomy is required go on to develop upper urinary tract tumors (Amling, 2001; Huguet-Perez, Palui, Millan-Rodriguez et al., 2001).
The predominant cause of bladder cancer today is cigarette smoking. Cancers arising from the prostate, colon, and rectum in males and from the lower gynecologic tract in females may metas-tasize to the bladder (Chart 45-14).
Bladder tumors usually arise at the base of the bladder and involve the ureteral orifices and bladder neck. Visible, painless hematuria is the most common symptom of bladder cancer. Infection of the urinary tract is a common complication, producing frequency, urgency, and dysuria. Any alteration in voiding or change in the urine, however, may indicate cancer of the bladder. Pelvic or back pain may occur with metastasis.
The diagnostic evaluation includes cystoscopy (the mainstay of diagnosis), excretory urography, a CT scan, ultrasonography, and bimanual examination with the patient anesthetized. Biopsies of the tumor and adjacent mucosa are the definitive diagnostic pro-cedures. Transitional cell carcinomas and carcinomas in situ shed recognizable cancer cells. Cytologic examination of fresh urine and saline bladder washings provide information about the prog-nosis, especially for patients at high risk for recurrence of primary bladder tumors (Amling, 2001).
Although mainstay diagnostic tools such as cytology and CT scanning have a high detection rate, they are costly. Newer diag-nostic indicators are being studied. Bladder tumor antigens, nu-clear matrix proteins, adhesion molecules, cytoskeletal proteins, and growth factors are being studied to support the early detec-tion and diagnosis of bladder cancer. There are an increasing number of molecular assays available for the detection of bladder cancer (Saad, Hanbury, McNicholas et al., 2001).
Treatment of bladder cancer depends on the grade of the tumor (the degree of cellular differentiation), the stage of tumor growth (the degree of local invasion and the presence or absence of metas-tasis), and the multicentricity (having many centers) of the tumor. The patient’s age and physical, mental, and emotional sta-tus are considered when determining treatment modalities.
Transurethral resection or fulguration (cauterization) may be per-formed for simple papillomas (benign epithelial tumors). These procedures, eradicate the tumors through surgical incision or electrical current with the use of instruments inserted through the urethra. After this bladder-sparing surgery, intravesical administration of BCG is the treat-ment of choice.
Management of superficial bladder cancers presents a challenge because there are usually widespread abnormalities in the bladder mucosa. The entire lining of the urinary tract, or urothelium, is at risk because carcinomatous changes can occur in the mucosa of the bladder, renal pelvis, ureter, and urethra. About 25% to 40% of superficial tumors recur after transurethral resection or fulgu-ration. Patients with benign papillomas should undergo cytology and cystoscopy periodically for the rest of their lives because ag-gressive malignancies may develop from these tumors.
A simple cystectomy (removal of the bladder) or a radical cystectomy is performed for invasive or multifocal bladder can-cer. Radical cystectomy in men involves removal of the bladder, prostate, and seminal vesicles and immediate adjacent perivesical tissues. In women, radical cystectomy involves removal of the blad-der, lower ureter, uterus, fallopian tubes, ovaries, anterior vagina, and urethra. It may include removal of pelvic lymph nodes. Re-moval of the bladder requires a urinary diversion procedure.
Although radical cystectomy remains the standard of care for invasive bladder cancer in the United States, researchers are ex-ploring trimodality therapy: transurethral resection of the blad-der tumor, radiation, and chemotherapy. This is in an effort to spare patients the need for cystectomy. A trimodality approach to transitional cell bladder cancer mandates lifelong surveillance with cystoscopy. Although most completely responding patients retain their bladders free from invasive relapse, one quarter de-velop superficial disease. This may be managed with transurethral resection of the bladder tumor and intravesical therapies but carries an additional risk that late cystectomy will be required (Zietman, Grocela & Zehr, 2001; Zietman, Shipley & Kaufman, 2000).
Chemotherapy with a combination of methotrexate, 5-fluorouracil, vinblastine, doxorubicin (Adriamycin), and cisplatin has been ef-fective in producing partial remission of transitional cell carci-noma of the bladder in some patients. Intravenous chemotherapy may be accompanied by radiation therapy. The development of new chemotherapeutic agents such as gemcitabine and the tax-anes has opened up promising new perspectives in the treatment of bladder cancer. However, the preliminary phase II data must be confirmed in adequately conducted phase III trials (Bellmunt & Albiol, 2001).
Topical chemotherapy (intravesical chemotherapy or instilla-tion of antineoplastic agents into the bladder, resulting in contact of the agent with the bladder wall) is considered when there is a high risk for recurrence, when cancer in situ is present, or when tumor resection has been incomplete. Topical chemotherapy de-livers a high concentration of medication (thiotepa, doxorubicin, mitomycin, ethoglucid, and BCG) to the tumor to promote tumor destruction. BCG is now considered the most effective in-travesical agent for recurrent bladder cancer because it enhances the body’s immune response to cancer.
Intravesical BCG is an immunotherapeutic agent that is given intravesically and is effective in the treatment of superficial tran-sitional cell carcinoma. BCG has a 43% advantage in preventing tumor recurrence, a significantly better rate than the 16% to 21% advantage of intravesical chemotherapy. In addition, BCG is par-ticularly effective in the treatment of carcinoma in situ, eradicat-ing it in more than 80% of cases. In contrast to intravesical chemotherapy, BCG has also been shown to decrease the risk of tumor progression.
The optimal course of BCG appears to be a 6-week course of weekly instillations, followed by a 3-week course at 3 months in tumors that do not respond. In high-risk cancers, maintenance BCG administered for 3 weeks every 6 months may limit recur-rence and prevent progression (Amling, 2001). The adverse ef-fects associated with this prolonged therapy, however, may limit its widespread applicability.
The patient is allowed to eat and drink before the instillation procedure, but once the bladder is full, the patient must retain the intravesical solution for 2 hours before voiding. At the end of the procedure, the patient is encouraged to void and to drink lib-eral amounts of fluid to flush the medication from the bladder.
Radiation of the tumor may be performed preoperatively to re-duce microextension of the neoplasm and viability of tumor cells, thus reducing the chances that the cancer may recur in the im-mediate area or spread through the circulatory or lymphatic sys-tems. Radiation therapy is also used in combination with surgery or to control the disease in patients with an inoperable tumor. The transitional cell variety of bladder cancer responds poorly to chemotherapy. Cisplatin, doxorubicin, and cyclophosphamide have been administered in various doses and schedules and ap-pear most effective.
Bladder cancer may also be treated by direct infusion of the cytotoxic agent through the bladder’s arterial blood supply to achieve a higher concentration of the chemotherapeutic agent with fewer systemic toxic effects. For more advanced bladder can-cer or for patients with intractable hematuria (especially after ra-diation therapy), a large, water-filled balloon placed in the bladder produces tumor necrosis by reducing the blood supply of the bladder wall (hydrostatic therapy). The instillation of formalin, phenol, or silver nitrate relieves hematuria and strangury (slow and painful discharge of urine) in some patients.
The use of photodynamic techniques in treating superficial blad-der cancer is under investigation. This procedure involves systemic injection of a photosensitizing material (hematoporphyrin), which the cancer cell picks up. A laser-generated light then changes the hematoporphyrin in the cancer cell into a toxic medication. This process is being investigated for patients in whom intravesical chemotherapy or immunotherapy has failed (Amling, 2001).
Copyright © 2018-2021 BrainKart.com; All Rights Reserved. (BS) Developed by Therithal info, Chennai.